?:abstract
|
-
Objective: Due to Covid-19 pandemic, the oncologists and cancer patients are in a dilemma, whether they should continue with the planned treatment or wait till the pandemic is over This review is intended to explore the management options for gynaecological cancers during the pandemic Data sources: We searched for literature from Pubmed database and oncological socities pertaining to the management of gynaecological cancers and Covid-19 pandemic Study Selection: For such once in a century pandemic, there is a paucity of evidence based literature Therefore, to address this issue all the available relevant studies were reviewed Results: Definitely, a deviation from a standard care for a longer period i e beyond 4-6 weeks may lead to a significant impact on over all outcomes As this current scenario is one of the first after the advent of modern medicine, there are no clear-cut evidence based suggestions to adopt for clinicians Various organizations like NCCN, ACS, SGO, ESMO have suggested few recommendations for present situation Here again, a role of multidisciplinary team is of pivotal importance and every case merits discussion by multi-disciplinary team (MDT) before finalizing a strategy We share our perspective on the issue, which is based on currently available evidences as well as the practices we intend to follow at our centre We agree that the quality of evidence remains of low grade and are mostly based on expert recommendations with an aim to tide over this period of around 4-12 weeks Conclusion: Precise triage of patients will play a pivotal role in preserving resources and protecting health care workers and patients The expertise at the respective oncology centres, prevalence/incidence of COVID-19 cases in that area, the support system of the hospital and the patient profile should direct the changes in practices We also recommend that the standard therapy should be resumed as soon as the situation improves
|